Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    OSE2101C301
Previous Study | Return to List | Next Study

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02654587
Recruitment Status : Active, not recruiting
First Posted : January 13, 2016
Last Update Posted : March 8, 2021
Sponsor:
Information provided by (Responsible Party):
OSE Immunotherapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 2020
Estimated Study Completion Date : December 2021